Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | CES2 | O00748 | 2/20 | 0.42 |
| ▸ | CES1 | P23141 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 4/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 2/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1689739 | 1.00 | HPGD (0.44) | HPGDSMN1; SMN2CES2CES1ALDH1A1 | |
| SCHEMBL3521887 | 0.81 | PDE4A (0.49) | HPGDSMN1; SMN2CES2CES1ALDH1A1 | |
| SCHEMBL1689658 | 0.80 | HPGD (0.46) | HPGDSMN1; SMN2CES2CES1ALDH1A1 | |
| SCHEMBL10277127 | 0.80 | PTGS1 (0.46) | HPGDSMN1; SMN2CES2CES1ALDH1A1 | |
| SCHEMBL1689657 | 0.80 | HPGD (0.46) | HPGDSMN1; SMN2CES2CES1ALDH1A1 | |
| SCHEMBL1689654 | 0.80 | HPGD (0.46) | HPGDSMN1; SMN2CES2CES1ALDH1A1 | |
| SCHEMBL10277125 | 0.80 | PTGS1 (0.46) | HPGDSMN1; SMN2CES2CES1ALDH1A1 | |
| SCHEMBL10277124 | 0.80 | PTGS1 (0.46) | HPGDSMN1; SMN2CES2CES1ALDH1A1 | |
| SCHEMBL7931264 | 0.79 | RAB9A (0.45) | HPGDSMN1; SMN2CES2CES1ALDH1A1 | |
| SCHEMBL7931260 | 0.79 | RAB9A (0.45) | HPGDSMN1; SMN2CES2CES1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1515969-B2 | SPIROINDOLINEPIPERIDINE DERIVATIVES | SYNGENTA LTD (GB) | 2017-10-11 | — | — | EP | disclosed |
| US-9686990-B2 | Spiroindolinepiperidine derivatives | SYNGENTA PARTICIPATIONS AG (CH) | 2017-06-27 | — | — | US | disclosed |
| US-20160007608-A1 | SPIROINDOLINEPIPERIDINE DERIVATIVES | SYNGENTA LIMITED (GB) | 2016-01-14 | — | — | US | disclosed |
| US-9174987-B2 | Spiroindolinepiperidine derivatives | SYNGENTA LIMITED (DE) | 2015-11-03 | — | — | US | disclosed |
| EP-1880996-B1 | SPIROINDOLINEPIPERIDINE DERIVATIVES | SYNGENTA LTD (GB) | 2014-12-24 | — | — | EP | disclosed |
| US-20120010220-A1 | SPIROINDOLINEPIPERIDINE DERIVATIVES | SYNGENTA CROP PROTECTION LLC (US) | 2012-01-12 | — | — | US | disclosed |
| EP-1515969-B1 | SPIROINDOLINEPIPERIDINE DERIVATIVES | SYNGENTA LTD (GB) | 2010-08-25 | — | — | EP | disclosed |
| EP-1880996-A1 | Spiroindolinepiperidine derivatives | Syngenta Limited (GB) | 2008-01-23 | — | — | EP | disclosed |
| US-20060106045-A1 | Spiroindolinepiperidine derivatives | SYNGENTA PARTICIPATIONS AG (CH) | 2006-05-18 | — | — | US | disclosed |
| EP-1515969-A1 | SPIROINDOLINEPIPERIDINE DERIVATIVES | Syngenta Limited (GB) | 2005-03-23 | — | — | EP | disclosed |
| WO-2003106457-A1 | SPIROINDOLINEPIPERIDINE DERIVATIVES | SYNGENTA LIMITED (GB) | 2003-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010220-A1 | SPIROINDOLINEPIPERIDINE DERIVATIVES | RECQL, OPRD1, SKP1 | HPGD 1299/4885SMN1; SMN2 935/4885CES2 2624/4885 |
| US-20060106045-A1 | Spiroindolinepiperidine derivatives | RECQL, OPRD1, NCAPD3 | HPGD 1286/4885SMN1; SMN2 1132/4885CES2 2393/4885 |
| US-20160007608-A1 | SPIROINDOLINEPIPERIDINE DERIVATIVES | RECQL, OPRD1, SKP1 | HPGD 1299/4885SMN1; SMN2 935/4885CES2 2624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.